THE 5<sup>th</sup> INTERNATIONAL MEETING ON INTESTINAL DISEASES IN CONJUNCTION WITH THE ANNUAL CONGRESS OF THE KOREAN ASSOCIATION FOR THE STUDY OF INTESTINAL DISEASES

MAY 12 THU - 14 SAT, 2022 / BEXCO, Busan IN PERSON & VIRTUAL EVENT >>>

# A Great Leap for Intestinal Research:

### **20 YEARS AND BEYOND**

# **Curriculum Vitae**

Personal Information		
Title (i.e. Pf., Dr., etc.)	Dr.	
Name (First name Middle name Last name)	Fraser	
Degree (i.e. MD, Msc, PhD, etc.)	MBChB FRCP DPhil	
Country	UK	
Affiliation	University Hospital Southampton NHS FT	

#### **Educational Background**

Dr Cummings did his gastroenterology clinical and research training in Oxford prior to taking up his consultant post in Southampton in 2009.

#### **Professional Experience**

I lead a large IBD service with over 5000 patients under active care with 1400patients on advanced therapies. We run a large research program focused on all aspects of patient care from basic science focused on epigenetics, macrophage function and epithelial barrier function, commercial phase I-IV studies, real world evidence generation as well as nutritional aspects of IBD. He is clinical lead for the UK IBD registry, a member of the BSG IBD section and contributes to the UK quality improvement program through IBDUK.

#### **Professional Organizations**

**British Society of Gastroenterology** 

ECCO



THE 5<sup>th</sup> International Meeting on Intestinal Diseases in Conjunction with the Annual Congress of the Korean Association for the Study of Intestinal Diseases

MAY 12 THU -14 SAT, 2022 / BEXCO, Busan IN PERSON & VIRTUAL EVENT ►►

## A Great Leap for Intestinal Research:

## **20 YEARS AND BEYOND**

#### **Main Scientific Publications**

Ventress E, Young D, Rahmany S, Harris C, Bettey M, Smith T, Moyses H, Lech M, Gwiggner M, Felwick R, **Cummings J R Fraser.** 

Transitioning from Intravenous to Subcutaneous Vedolizumab in Patients with Inflammatory Bowel Disease [TRAVELESS] *Journal of Crohn's and Colitis in press* 

Innovative approaches to biologic development on the trail of CT-P13: biosimilars, value-added medicines, and biobetters

Kim H, Alten R, Cummings F et al MAbs 2021;13(1)

Dharmasiri S, Garrido-Martin EM, Harris RJ, Cummings JRF, Sanchez-Elsner T.

High throughput RNA-seq of intestinal macrophages demonstrates profound alteration of gene expression identifying a co-ordinating role for macrophages in the pathogenesis of IBD.

Inflamm Bowel Dis. 2021 Oct 18;27(10):1641-1652

Razanskaite V, Bettey M, Downey L, Wright J, Callaghan J, Rush M, Whiteoak S, Kerr S, Perry K, Underhill C, Efrem E, Ahmed I, **Cummings JRF** 

Biosimilar infliximab in Inflammatory Bowel Disease: outcomes of a managed switching program.

J Crohns Colitis 2017 1;11(6):690-696